Introduction
The advent of cardiac stimulation devices has revolu tionised the treatment of various cardiac disorders, from syncope to arrhythmias and, more recently, in the field of heart failure. During the twentieth century, several milestones were reached leading to the current state of cardiac stimulation, from the first successful use of an external electrical stimulation device in 1932 by Albert S. Hyman [1] to the first implantable epicar dial pacemaker by Rune Elmquist and Ake Senning in 1958 [2] . In parallel, interest in development of trans venous lead systems grew, with the first implantation of a temporary transvenous pacing lead in 1958 by Sey mour Furman [3] , and, finally, the appearance of the first implantable permanent pacemaker systems with transvenous leads in 1962 [4] .
Currently, most cardiac implantable electronic devices consist of a pulse generator implanted in the sub cutaneous or submuscular tissue, connected to one or more transvenous leads implanted on the endocardial surface of the right chambers or the coronary sinus.
The surgical implantation procedure, though a fre quently performed intervention in most centres, can
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Key words: leadless pacemaker; intracardiac pacemaker; cardiac pacing; left ventricular endocardial pacing; ultrasound-based cardiac resynchronisation therapy have complications in almost 10% of cases [5, 6] . These include h aematoma (2-3%) a nd i nfection (approxi mately 1%) at the pocket site, as well as cardiac perfora tion (0.4-0.6%), lead dislodgment (2-3%) and pneumo thorax ( around 2%) following placement of t he transvenous leads. Further leadrelated concerns after device implantation include fracture, insulation de fects, connector problems and infection. Despite great advances in pacemaker and lead technologies, these issues are far from being resolved and may even be growing in importance owing to the increasing num ber of devices and leadsperdevice implanted. Indeed, the morbidity associated with devicerelated complica tions remains high, and these complications must be balanced against the potential benefit in this popula tion of often very elderly patients.
Since early on, research has investigated the possibility of dispensing with the leads and external generators altogether as one way potentially to eliminate these issu es. The feasibility of i ntracardiac stimulation devices was demonstrated from as early as 1970, with several reports of successful implantation and short term function in canine models [7, 8] . Though these devices showed great promise, it was not until more re cently that the research community and industry have accelerated the development of human leadless pace makers. At first, the concept of leadless devices still required the implantation of an extracardiac genera tor that would transmit wirelessly to an intracardiac receiver, either by ultrasound energy [9] [10] [11] or mag netic fieldinduction energy [12] . However, since 2012, 
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Characteristics of the different leadless pacing systems
Right ventricular pacing devices
The first fully intracardiac leadless pacing system to be developed was the Nanostim TM Leadless Cardiac Pace Until recently, this required a transvenous approach with passage through the atrial or ventricular septum, but with a high rate of systemic thromboembolism [13] .
Thus, wireless left ventricular endocardial pacing is also being developed in order to address these issues. is necessary in order to synchronise LV pacing with RV pacing, using a programmed 3ms delay.
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Implantation procedures of leadless devices Right ventricular pacing systems
Both devices can be implanted under local anaesthesia and fluoroscopic guidance. The delivery systems con tain a deflectable tip that is directed through the right atrium and into the RV via the tricuspid valve. Ideally, the devices are directed to the apical or apicoseptal regi on. Once i n position, the implantation of the Nanostim™ LCP device requires retraction of an ex tendable protective sleeve, exposing the helix, which is then r otated 1 .25 turns, enabling fixation [ 14] . T he Micra™ i mplantation a lso requires r etraction o f a sleeve, thus deploying the four tines, of which at least two should hook into the myocardium for a successful deployment. Once fixated, both devices are undocked, but remain tethered to the delivery system, allowing evaluation of stability and pacing performance, and easy repositioning if necessary. Before final release, the operator performs a "pull and hold" under fluoros copy, then cuts the tethers, freeing the device. Figure 3 illustrates the implantation procedure of the Micra™ TPS system. Apart from formal training by the manu facturers of the different devices, operators undertak ing implantation of leadless devices should be experi enced in femoral access as well as cardiac stimulation.
It is a significant asset to have experience with electro physiological procedures, as steering of the catheter re lates more to this domain than to manipulation of pac ing leads. Furthermore, the physician should ideally be competent in lead extraction, as he or she will be more proficient with largebore femoral access as well as device retrieval in case of need. Device implantation should ideally be undertaken in an environment with highquality fluoroscopy such as an electrophysiology or catheterisation laboratory, especially with the Mi cra™ system as correct visualisation of the four tines is mandatory for adequate device placement.
Wireless cardiac resynchronisation therapy system
The leadless receiver is implanted in the LV endocar dium via a retrograde aortic approach, and anchored with the help of three selfexpanding nitinol tines. The optimal position of the pulse generator in the WiCS™ system is chosen with use of echocardiography in order to find an appropriate acoustic window. Usually this window is found lateral to the left parasternal re gion in the fourth to sixth intercostal spaces, the fifth intercostal often being the most appropriate [15] .
Current scientific evidence regarding leadless pacing technology Micra™ Transcatheter Pacing System
After initial feasibility studies performed in animals In terms of safety endpoints, the overall rate of major procedure o r systemrelated adverse effects a t 6 months was 3.45%, corresponding to 28 complications in 25 patients, 4 of whom had unsuccessful implants. A. The delivery system is introduced via the femoral vein into the right atrium via a super-stiff guidewire.
B.
The Micra™ unit is introduced into the deflectable delivery system and positioned across the tricuspid valve into the right ventricle.
C. The apical septum is targeted using contrast injection.
D.
The delivery sheath is withdrawn, thus deploying the tines into the ventricular wall.
E.
A "pull and hold" test is performed, with viewing in multiple planes to verify that at least two of four tines are fixated, and the tether is then cut to free the device. patients. Overall, however, the implant procedure was well tolerated in the Micra TPS study, with a mean time to discharge of 1 day in the analysis of the first 140 pa tients [17] .
The system has been available for limited market re lease in Switzerland since June 2015.
Nanostim™ Leadless Cardiac Pacemaker
The LEADLESS study [14] was a multicentre, singlearm European study evaluating the safety and efficacy of the Nanostim™ LCP device in 33 patients. Similarly to the Micra TPS study, patients were included if they had an indication for singlechamber pacing, consisting of: (1) More recently, interim results of the LEADLESS II study, a prospective, nonrandomised, multicentre study aimed at obtaining FDA approval for the Nanostim™ device, have been published [24] . The primary analysis concerned the 6month safety and efficacy results of the first 300 patients, but the study also published the outcomes of all 526 patients enrolled to date. Inclusion and exclusion criteria were similar for the LEADLESS trial, although pacemakerdependant patients were no longer excluded. The results showed a Nanostim™ im plantation success rate of 95.8%, with a mean proce dure time of 28.6 ± 17.8 minutes, and fluoroscopy time of 13.9 ± 9.1 minutes, once again significantly longer than for a transvenous VVI pacemaker. Similarly to the LEADLESS trial, 70.2% of devices were successfully im planted after initial deployment. Mean hospital stay was comparable to that in the Micra TPS study (1.1 ± 1.7 days). Regarding pacemaker efficacy at 6 months, 90% of patients reached the combined primary efficacy endpoint of (1) acceptable pacing threshold (≤2.0 V at 0.4 msec) and (2) an acceptable sensing amplitude (R wave ≥5.0 mV, or a value equal to or greater than the value at implantation). In the total cohort, the mean values at 12 months were: Rwave amplitude 9.2 ± 2.9 mV and pacing capture threshold (at 0.4 msec) 0.58 ± 0.31 V. According to results at the 6month followup, battery longevity could be estimated to be 15 ± 6.7 years.
With regards to safety, the rate of devicerelated seri ous adverse events was 6.7% over 6 months, with 1.3% cardiac perforation, 1.7% device dislodgement, 1.3% el evated pacing thresholds necessitating device retrieval and replacement, a nd 1 .3% vascular complications.
This study also pointed to a learning curve, as in most medical procedures, with an almost halved rate of complications after 1 0 procedures ( 3.6 vs 6.8%), al though this difference was not statistically significant.
Of n ote, another longterm s afety trial is o ngoing in E urope (The L EADLESS Observational Study; NCT02051972).
Wireless cardiac resynchronisation therapy system
Initial evaluation of the WiCS™ device was performed in the WISECRT study [15] , which was a multicentre 
Remaining questions Leadless right ventricular pacing
To date, no data exist regarding the actual battery longe vity of leadless pacemakers, the only indications coming f rom theoretical calculations or estimates based on early results of the aforementioned studies.
Moreover, much of the data was retrieved from non pacemakerdependant patents, such as in the LEAD LESS trial. Even in the LEADLESS II trial, mean rates of ventricular pacing were 51.6% at 12 months. Never theless, these estimates point toward similar device longevity to single chamber conventional pacemakers.
In the case of the Nanostim™, the high efficiency of the unit results in a current drain of approximately 1 µA, around six times less than a transvenous unit from the same manufacturer [22] . As illustrated in table 1 
Leadless endocardial left ventricular pacing
The efficacy results of the WiseCRT and SELECTLV trials seem to indicate the systems could be a useful alternative to standard CRT systems in cases of nonre sponse or LV lead failure, but data are available for only a short followup of 6 months. Obviously the main con cern with the system remains the safety of the implan tation procedure, which is not fully addressed, as well as the currently unknown rate of chronic complica tions.
Other concerns are the seemingly short battery life of the device; in the WiseCRT study, projected battery longevity after 6 months followup was only 18 months (range 9-42 months). Ease of extraction and/or replace ment of the different devices contained in the system remains unknown. I ssues with r estricted acoustic windows that limit energy transmission need to be addressed. Finally, the thromboembolic risk linked to the leadless receiver unit in the LV in comparison with standard transvenous LV leads needs to be further studied.
Future directions
One important issue that will be addressed in the fu ture is the possibility of multichamber leadless pacing, although anchoring the device in a safe and effective manner in the thinwalled atrium, and issues with additional energy requirements resulting with com munication between the devices, need to be addressed.
Currently the available RV pacing devices only allow [6, 29] . The combination of leadless devices with the subcutaneous defibrillator (Boston Scientific, Marlborough, MA, USA) will allow antitachycardia and antibradycardia pacing, and will be introduced in the near future. Finally, researchers are working on a device which will harvest kinetic en ergy from the heart's motion for providing powerthereby dispensing of the need for device replacement.
Conclusions
Leadless pacemakers are a milestone in pacing ther apy. They are clearly the preferred pacing modality in a niche group of patients (e.g., those with venous access issues), but they can be considered in other situations where VVI(R) pacing is indicated. Currently, only one system is commercially available in Switzerland, with a limited market release. The implantation procedure requires special skills that need to be acquired prop erly, as complications such as tamponade are a con cern. Other issues are management at battery deple tion, extractability, and cost (which is likely to evolve depending upon the uptake of the technology and the introduction of new models from competitors). The therapy will no doubt continue to evolve, and provide us with more treatment options for our patients.
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